A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Galecto, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 579,300 shares of GLTO stock, worth $4.24 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
579,300
Previous 578,983 0.05%
Holding current value
$4.24 Million
Previous $452,000 39.82%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$0.47 - $0.76 $148 - $240
317 Added 0.05%
579,300 $272,000
Q1 2024

May 13, 2024

BUY
$0.6 - $0.89 $103,209 - $153,093
172,015 Added 42.27%
578,983 $452,000
Q4 2023

Feb 13, 2024

BUY
$0.52 - $0.78 $104,971 - $157,457
201,868 Added 98.42%
406,968 $293,000
Q3 2023

Nov 14, 2023

BUY
$0.56 - $3.17 $21,973 - $124,387
39,239 Added 23.66%
205,100 $148,000
Q2 2023

Aug 11, 2023

BUY
$1.68 - $2.84 $16,398 - $27,721
9,761 Added 6.25%
165,861 $418,000
Q1 2023

May 12, 2023

BUY
$1.21 - $2.86 $2,541 - $6,006
2,100 Added 1.36%
156,100 $311,000
Q4 2022

Feb 13, 2023

SELL
$1.06 - $58.5 $26,818 - $1.48 Million
-25,300 Reduced 14.11%
154,000 $177,000
Q3 2022

Nov 14, 2022

SELL
$1.59 - $60.0 $107,183 - $4.04 Million
-67,411 Reduced 27.32%
179,300 $339,000
Q2 2022

Aug 12, 2022

BUY
$1.22 - $2.74 $25,067 - $56,298
20,547 Added 9.09%
246,711 $427,000
Q1 2022

May 13, 2022

SELL
$1.72 - $3.31 $6,941 - $13,359
-4,036 Reduced 1.75%
226,164 $498,000
Q4 2021

Feb 11, 2022

BUY
$2.3 - $3.58 $292,790 - $455,734
127,300 Added 123.71%
230,200 $698,000
Q3 2021

Nov 12, 2021

BUY
$3.59 - $5.0 $226,888 - $316,000
63,200 Added 159.19%
102,900 $369,000
Q2 2021

Aug 13, 2021

BUY
$4.63 - $8.0 $183,811 - $317,600
39,700 New
39,700 $201,000

Others Institutions Holding GLTO

About Galecto, Inc.


  • Ticker GLTO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,395,700
  • Market Cap $186M
  • Description
  • Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...
More about GLTO
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.